Quest Diagnostics (DGX) DIvidends Date & History

Key Takeaways

• Quest Diagnostics offers a current dividend yield of 1.76% with a quarterly payment of $0.86 per share, annualizing to $3.44.
• The company has raised its dividend for 15 consecutive years, with a recent 7.5% increase announced in February 2026.
• Payout ratio stands at approximately 37%, indicating strong sustainability backed by earnings and free cash flow.
• Recent ex-dividend date was April 6, 2026, with payment on April 20, 2026.
• Dividend growth averages about 7% over the past five years, appealing to income-focused investors.
• Free cash flow of $1.4 billion in 2025 comfortably covers dividend obligations.

Dividend Overview

Quest Diagnostics (DGX), a leading provider of diagnostic information services, maintains a consistent quarterly dividend policy. The current quarterly dividend is $0.86 per share, equating to an annual payout of $3.44 and a yield of 1.76% based on recent stock prices. Payments are made every three months, with the most recent ex-dividend date on April 6, 2026, and payment on April 20, 2026. This positions DGX as a dividend growth stock rather than a high-yield play, emphasizing steady increases over yield maximization. The company's commitment to shareholder returns is evident in its long-term strategy of balancing dividends with share repurchases and reinvestment in core diagnostics operations.

Dividend History and Growth

Quest Diagnostics has a robust dividend history, with quarterly payments since 2011 and annual increases for 15 straight years. The dividend per share has grown from $1.80 in 2017 to $3.44 annualized in 2026, reflecting a compound annual growth rate (CAGR) of approximately 7% over the past five years. Notable recent hikes include a 6.7% increase to $0.80 in early 2025 and a 7.5% jump to $0.86 in February 2026. There have been no cuts, underscoring payment consistency even through economic cycles. This track record aligns with the company's strategy of returning capital to shareholders while funding growth in advanced diagnostics.

Dividend Sustainability and Payout Ratio

The dividend appears highly sustainable, supported by a trailing payout ratio of about 37%, well below 60% thresholds often cited for safety. Earnings per share comfortably cover the payout, with forward estimates suggesting even lower ratios around 35%. Free cash flow (FCF) reached $1.4 billion in 2025, providing ample coverage—dividends consumed roughly 27% of FCF. Debt levels are manageable, with long-term debt at $5.7 billion and a debt-to-EBITDA ratio of around 3x, bolstered by strong operating cash flows exceeding $1.8 billion annually. These metrics indicate robust financial health, reducing risks to ongoing payments.

Dividend Compared to Industry Peers

In the diagnostics and medical laboratories industry, Quest Diagnostics' 1.76% yield stands above the peer average. Primary competitor Labcorp Holdings (LH) offers a lower 1.06% yield with a 27% payout ratio. Broader healthcare services yields hover around 1-2%, making DGX's profile competitive—higher yield than LH paired with a superior growth streak. This positions DGX favorably for investors seeking reliable income in a low-yield sector dominated by growth-oriented firms.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research today.

Is This Stock Attractive for Dividend Investors?

Quest Diagnostics appeals to dividend growth investors prioritizing consistency over high yields, given its 15-year streak and mid-single-digit annual hikes. Conservative income seekers may value the low payout ratio and FCF coverage, offering stability in the defensive diagnostics sector. Long-term holders could appreciate the balance of 1.76% yield, share buybacks, and exposure to steady healthcare demand. However, yield chasers might look elsewhere, as it trails higher-payers in other sectors. The stock suits portfolios emphasizing quality compounders with moderate income, but volatility from reimbursement pressures or competition warrants monitoring. Overall, it fits balanced dividend strategies focused on sustainability rather than aggressive income.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations